PRLD
Prelude Therapeutics Incorporated
Price Chart
Latest Quote
$4.32
-0.03 (-0.69%)
Current Price
| Previous Close | $4.35 |
| Open | $4.30 |
| Day High | $4.64 |
| Day Low | $4.16 |
| Volume | 1,076,626 |
Stock Information
| Shares Outstanding | 64.92M |
| Total Debt | $17.72M |
| Cash Equivalents | $81.55M |
| Revenue | $16.72M |
| Net Income | $-77.80M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $344.07M |
| EPS (TTM) | $-1.00 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $364.61M |
| Sales | $16.72M |
| Income | $-77.80M |
| Book/sh | $0.73 |
| Cash/sh | $1.26 |
| Employees | 79 |
Financial Ratios
| Quick Ratio | 1.96 |
| Current Ratio | 2.03 |
| Debt/Eq | 29.45 |
Returns & Margins
| ROA | -39.69% |
| ROE | -95.25% |
| Gross Margin | 100.00% |
| Operating Margin | -309.54% |
Ownership
| Insider Ownership | 13.80% |
| Institutional Ownership | 64.54% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.60 |
| P/S | 20.58 |
| P/B | 5.93 |
Analyst Data
| Recommendation | none |
| Target Price | $8.00 |
Technical Indicators
| SMA20 | $4.06 |
| SMA50 | $4.38 |
| SMA200 | $2.65 |
| RSI | 58.26 |
| ATR | 0.3430 |
| Shares Float | 27.59M |
| Short Float | 6.73% |
| Short Ratio | 3.84 |
| Volatility | 1.01 |
| Rel Volume | 3.25 |
Performance History
| Week | +5.11% |
| Month | +1.17% |
| Quarter | +35.42% |
| 6 Months | +117.09% |
| YTD | +58.24% |
| Year | +365.52% |
| 3 Years | -22.72% |
| 5 Years | -86.15% |
| 10 Years | -83.51% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $4.32 | 1,076,600 |
| 2026-06-17 | $4.35 | 317,600 |
| 2026-06-16 | $4.20 | 450,500 |
| 2026-06-15 | $4.46 | 327,400 |
| 2026-06-12 | $4.49 | 314,300 |
| 2026-06-11 | $4.11 | 204,900 |
| 2026-06-10 | $3.95 | 192,700 |
| 2026-06-09 | $3.94 | 235,400 |
| 2026-06-08 | $3.84 | 281,300 |
| 2026-06-05 | $3.81 | 220,900 |
| 2026-06-04 | $4.08 | 399,900 |
| 2026-06-03 | $3.66 | 375,800 |
| 2026-06-02 | $3.50 | 385,000 |
| 2026-06-01 | $3.82 | 237,800 |
| 2026-05-29 | $3.92 | 288,200 |
| 2026-05-28 | $3.93 | 373,200 |
| 2026-05-27 | $4.16 | 170,900 |
| 2026-05-26 | $4.09 | 311,100 |
| 2026-05-22 | $4.27 | 241,600 |
| 2026-05-21 | $4.33 | 220,600 |
| 2026-05-20 | $4.50 | 386,100 |
| 2026-05-19 | $4.27 | 404,300 |
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
đ° Latest News
Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD)
Insider Monkey âĸ 2026-05-31T10:55:35Z
Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Simply Wall St. âĸ 2026-05-16T14:22:58Z
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet
Zacks âĸ 2026-05-08T13:55:04Z
Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer
Insider Monkey âĸ 2026-05-01T09:24:14Z
Myriad Genetics And 2 Other Penny Stocks To Watch Closely
Simply Wall St. âĸ 2026-04-06T18:05:14Z
Sana Biotechnology (SANA) Appoints Industry Veteran Brian Piper as New CFO
Insider Monkey âĸ 2026-02-26T19:27:44Z
Definitive Healthcare And 2 Other Promising Penny Stocks
Simply Wall St. âĸ 2026-01-28T18:05:37Z
Retail investors in Prelude Therapeutics Incorporated (NASDAQ:PRLD) are its biggest bettors, and their bets paid off as stock gained 12% last week
Simply Wall St. âĸ 2026-01-26T12:39:21Z
December 2025's Intriguing Stocks Priced Below Estimated Value
Simply Wall St. âĸ 2025-12-30T17:38:06Z
3 Promising Penny Stocks With A Market Cap Below $400M
Simply Wall St. âĸ 2025-12-30T12:05:18Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $12,140,000 | $7,000,000 | $0 | $0 |
| Operating Revenue | $12,140,000 | $7,000,000 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $116,706,000 | $146,714,000 | $132,277,000 | $123,540,000 |
| Other Income Expense | $5,068,000 | $12,541,000 | $10,445,000 | $8,102,000 |
| Other Non Operating Income Expenses | $5,068,000 | $12,541,000 | $10,445,000 | $8,102,000 |
| Operating Expense | $116,706,000 | $146,714,000 | $132,277,000 | $123,540,000 |
| General And Administrative Expense | $22,406,000 | $28,719,000 | $28,884,000 | $30,651,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-99,498,000 | $-127,173,000 | $-121,832,000 | $-115,438,000 |
| Normalized Income | $-99,498,000 | $-127,173,000 | $-121,832,000 | $-115,438,000 |
| Net Income From Continuing And Discontinued Operation | $-99,498,000 | $-127,173,000 | $-121,832,000 | $-115,438,000 |
| Total Operating Income As Reported | $-104,566,000 | $-139,714,000 | $-132,277,000 | $-123,540,000 |
| Net Income Common Stockholders | $-99,498,000 | $-127,173,000 | $-121,832,000 | $-115,438,000 |
| Net Income | $-99,498,000 | $-127,173,000 | $-121,832,000 | $-115,438,000 |
| Net Income Including Noncontrolling Interests | $-99,498,000 | $-127,173,000 | $-121,832,000 | $-115,438,000 |
| Net Income Continuous Operations | $-99,498,000 | $-127,173,000 | $-121,832,000 | $-115,438,000 |
| Pretax Income | $-99,498,000 | $-127,173,000 | $-121,832,000 | $-115,438,000 |
| Operating Income | $-104,566,000 | $-139,714,000 | $-132,277,000 | $-123,540,000 |
| Per Share | ||||
| Diluted EPS | $-1.29 | $-1.68 | $-2.02 | $-2.44 |
| Basic EPS | $-1.29 | $-1.68 | $-2.02 | $-2.44 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-102,855,000 | $-137,942,000 | $-131,108,000 | $-122,216,000 |
| Reconciled Depreciation | $1,711,000 | $1,772,000 | $1,169,000 | $1,324,000 |
| EBITDA (Bullshit earnings) | $-102,855,000 | $-137,942,000 | $-131,108,000 | $-122,216,000 |
| EBIT | $-104,566,000 | $-139,714,000 | $-132,277,000 | $-123,540,000 |
| Diluted Average Shares | $76,956,194 | $75,805,840 | $60,357,052 | $47,371,589 |
| Basic Average Shares | $76,956,194 | $75,805,840 | $60,357,052 | $47,371,589 |
| Diluted NI Availto Com Stockholders | $-99,498,000 | $-127,173,000 | $-121,832,000 | $-115,438,000 |
| Research And Development | $94,300,000 | $117,995,000 | $103,393,000 | $92,889,000 |
| Selling General And Administration | $22,406,000 | $28,719,000 | $28,884,000 | $30,651,000 |
| Other Gand A | $22,406,000 | $28,719,000 | $28,884,000 | $30,651,000 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $68,637,000 | $131,459,000 | $237,090,000 | $195,437,000 |
| Total Assets | $141,315,000 | $175,515,000 | $277,665,000 | $220,500,000 |
| Total Non Current Assets | $35,623,000 | $39,620,000 | $42,076,000 | $16,120,000 |
| Other Non Current Assets | $3,345,000 | $4,154,000 | $4,339,000 | $9,420,000 |
| Current Assets | $105,692,000 | $135,895,000 | $235,589,000 | $204,380,000 |
| Other Current Assets | $2,478,000 | $2,281,000 | $2,654,000 | $2,652,000 |
| Cash Cash Equivalents And Short Term Investments | $103,214,000 | $133,614,000 | $232,935,000 | $201,728,000 |
| Cash And Cash Equivalents | $35,256,000 | $12,474,000 | $25,291,000 | $30,605,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $17,789,000 | $18,025,000 | $16,888,000 | $1,832,000 |
| Long Term Debt And Capital Lease Obligation | $15,045,000 | $15,325,000 | $15,407,000 | $0 |
| Current Debt And Capital Lease Obligation | $2,744,000 | $2,700,000 | $1,481,000 | $1,832,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $72,678,000 | $44,056,000 | $40,575,000 | $25,063,000 |
| Total Non Current Liabilities Net Minority Interest | $19,684,000 | $18,415,000 | $18,746,000 | $3,361,000 |
| Other Non Current Liabilities | $2,841,000 | $3,090,000 | $3,339,000 | $3,361,000 |
| Non Current Deferred Liabilities | $1,798,000 | $0 | - | - |
| Current Liabilities | $52,994,000 | $25,641,000 | $21,829,000 | $21,702,000 |
| Other Current Liabilities | $965,000 | $771,000 | $945,000 | $524,000 |
| Current Deferred Liabilities | $33,734,000 | $0 | - | - |
| Payables And Accrued Expenses | $8,413,000 | $13,148,000 | $10,246,000 | $13,664,000 |
| Payables | $3,983,000 | $7,732,000 | $4,580,000 | $6,777,000 |
| Accounts Payable | $3,983,000 | $7,732,000 | $4,580,000 | $6,777,000 |
| Equity | ||||
| Common Stock Equity | $68,637,000 | $131,459,000 | $237,090,000 | $195,437,000 |
| Total Equity Gross Minority Interest | $68,637,000 | $131,459,000 | $237,090,000 | $195,437,000 |
| Stockholders Equity | $68,637,000 | $131,459,000 | $237,090,000 | $195,437,000 |
| Gains Losses Not Affecting Retained Earnings | $8,000 | $35,000 | $223,000 | $-1,692,000 |
| Other Equity Adjustments | $8,000 | $35,000 | $223,000 | $-1,692,000 |
| Retained Earnings | $-683,061,000 | $-583,563,000 | $-456,390,000 | $-334,558,000 |
| Other | ||||
| Ordinary Shares Number | $62,953,628 | $55,149,118 | $54,914,254 | $47,899,031 |
| Share Issued | $62,953,628 | $55,149,118 | $54,914,254 | $47,899,031 |
| Tangible Book Value | $68,637,000 | $131,459,000 | $237,090,000 | $195,437,000 |
| Invested Capital | $68,637,000 | $131,459,000 | $237,090,000 | $195,437,000 |
| Working Capital | $52,698,000 | $110,254,000 | $213,760,000 | $182,678,000 |
| Capital Lease Obligations | $17,789,000 | $18,025,000 | $16,888,000 | $1,832,000 |
| Total Capitalization | $68,637,000 | $131,459,000 | $237,090,000 | $195,437,000 |
| Additional Paid In Capital | $751,684,000 | $714,982,000 | $693,252,000 | $531,682,000 |
| Capital Stock | $6,000 | $5,000 | $5,000 | $5,000 |
| Common Stock | $6,000 | $5,000 | $5,000 | $5,000 |
| Non Current Deferred Revenue | $1,798,000 | $0 | - | - |
| Long Term Capital Lease Obligation | $15,045,000 | $15,325,000 | $15,407,000 | $0 |
| Current Deferred Revenue | $33,734,000 | $0 | - | - |
| Current Capital Lease Obligation | $2,744,000 | $2,700,000 | $1,481,000 | $1,832,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $7,138,000 | $9,022,000 | $9,157,000 | $5,682,000 |
| Current Accrued Expenses | $4,430,000 | $5,416,000 | $5,666,000 | $6,887,000 |
| Net PPE | $32,278,000 | $35,466,000 | $37,737,000 | $6,700,000 |
| Accumulated Depreciation | $-6,929,000 | $-5,258,000 | $-3,566,000 | $-3,319,000 |
| Gross PPE | $39,207,000 | $40,724,000 | $41,303,000 | $10,019,000 |
| Leases | $1,706,000 | $1,700,000 | $1,582,000 | $875,000 |
| Other Properties | $35,096,000 | $36,619,000 | $37,055,000 | $7,420,000 |
| Machinery Furniture Equipment | $2,405,000 | $2,405,000 | $2,328,000 | $87,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $67,958,000 | $121,140,000 | $207,644,000 | $171,123,000 |
| Construction In Progress | - | $0 | $338,000 | $1,637,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-56,369,000 | $-103,652,000 | $-110,576,000 | $-86,748,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-56,302,000 | $-102,888,000 | $-107,063,000 | $-83,729,000 |
| Cash Flow From Continuing Operating Activities | $-56,302,000 | $-102,888,000 | $-107,063,000 | $-83,729,000 |
| Investing Activities | ||||
| Capital Expenditure | $-67,000 | $-764,000 | $-3,513,000 | $-3,019,000 |
| Investing Cash Flow | $53,459,000 | $90,191,000 | $-34,646,000 | $81,691,000 |
| Cash Flow From Continuing Investing Activities | $53,459,000 | $90,191,000 | $-34,646,000 | $81,691,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $24,875,000 | $0 | $135,731,000 | $0 |
| Financing Cash Flow | $24,816,000 | $-120,000 | $136,395,000 | $815,000 |
| Cash Flow From Continuing Financing Activities | $24,816,000 | $-120,000 | $136,395,000 | $815,000 |
| Net Other Financing Charges | $-17,000 | $-164,000 | $-17,000 | - |
| Net Common Stock Issuance | $24,875,000 | $0 | $135,731,000 | $0 |
| Common Stock Issuance | $24,875,000 | $0 | $135,731,000 | $0 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-208,000 | $-395,000 | $0 | - |
| End Cash Position | $38,491,000 | $16,518,000 | $29,335,000 | $34,649,000 |
| Beginning Cash Position | $16,518,000 | $29,335,000 | $34,649,000 | $35,872,000 |
| Changes In Cash | $21,973,000 | $-12,817,000 | $-5,314,000 | $-1,223,000 |
| Proceeds From Stock Option Exercised | $166,000 | $439,000 | $681,000 | $815,000 |
| Net Issuance Payments Of Debt | $-208,000 | $-395,000 | $0 | - |
| Net Long Term Debt Issuance | $-208,000 | $-395,000 | $0 | - |
| Long Term Debt Payments | $-208,000 | $-395,000 | $0 | - |
| Net Investment Purchase And Sale | $53,526,000 | $90,955,000 | $-31,133,000 | $84,710,000 |
| Sale Of Investment | $154,392,000 | $143,649,000 | $190,500,000 | $203,933,000 |
| Purchase Of Investment | $-100,866,000 | $-52,694,000 | $-221,633,000 | $-119,223,000 |
| Net PPE Purchase And Sale | $-67,000 | $-764,000 | $-3,513,000 | $-3,019,000 |
| Purchase Of PPE | $-67,000 | $-764,000 | $-3,513,000 | $-3,019,000 |
| Change In Working Capital | $28,409,000 | $4,216,000 | $-10,479,000 | $932,000 |
| Change In Other Working Capital | $35,532,000 | - | - | - |
| Change In Other Current Liabilities | $-28,000 | $1,051,000 | $-1,624,000 | $-1,711,000 |
| Change In Payables And Accrued Expense | $-6,898,000 | $2,497,000 | $252,000 | $6,486,000 |
| Change In Accrued Expense | $-2,980,000 | $-808,000 | $2,522,000 | $6,833,000 |
| Change In Payable | $-3,918,000 | $3,305,000 | $-2,270,000 | $-347,000 |
| Change In Account Payable | $-3,918,000 | $3,305,000 | $-2,270,000 | $-347,000 |
| Change In Prepaid Assets | $-197,000 | $668,000 | $-9,107,000 | $-3,843,000 |
| Other Non Cash Items | $1,534,000 | $1,591,000 | $1,936,000 | $1,718,000 |
| Stock Based Compensation | $11,913,000 | $21,345,000 | $25,616,000 | $25,144,000 |
| Amortization Of Securities | $-371,000 | $-4,639,000 | $-3,473,000 | $2,591,000 |
| Depreciation Amortization Depletion | $1,711,000 | $1,772,000 | $1,169,000 | $1,324,000 |
| Depreciation And Amortization | $1,711,000 | $1,772,000 | $1,169,000 | $1,324,000 |
| Net Income From Continuing Operations | $-99,498,000 | $-127,173,000 | $-121,832,000 | $-115,438,000 |
| Gain Loss On Sale Of PPE | - | - | - | - |
Fetched: 2026-06-20